Brand Name :
Didronel
Synonyms :
etidronate
Class :
Calcium Metabolism Modifiers
Dosage Forms & Strengths
Tablet
200mg
400mg
5 - 10
mg/kg
Orally
every day
and do not exceed 6 months
do not exceed 20 mg/kg/day
Total hip replacement :
20
mg/kg
Orally
every day
1
month
before and 3 months post-surgery for 4 months
Spinal cord injury
Total 12 weeks dose: 20 mg/kg orally every day for 2 weeks, following 10 mg/kg every day for10 weeks
may diminish the serum concentration of polyvalent cation-containing products
may increase the risk or severity of methemoglobinemia when miltefosine is combined
may diminish the serum concentration of Polyvalent Cation Containing Products
aluminum hydroxide/magnesium carbonate
may decrease the serum concentration of Polyvalent Cation Containing Products
may decrease the serum concentration of Polyvalent Cation Containing Products
may diminish the serum concentration of polyvalent cation-containing products
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may increase the hypo calcaemic effect
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of angiogenesis inhibitors
may enhance the hypocalcemic effect
may enhance the hypocalcemic effect
may enhance the hypocalcemic effect
may enhance the hypocalcemic effect
may enhance the hypocalcemic effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
neomycin/polymyxin B/bacitracin topical
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
It may increase the nephrotoxic effect when combined with Bisphosphonate Derivatives
It may increase the toxic effect when combined with Bisphosphonate Derivatives
It may enhance the risk of adverse effects when combined with Phosphodiesterase inhibitors
Adverse drug reactions
Frequency Defined
1-10%
Hypocalcemia
Hypomagnesemia
Convulsion
Abnormal renal function
Fever
Bone pain
Hypophosphatemia
Frequency Not Defined
Hallucination
Headache
Amnesia
Depression
Confusion
Pregnancy warnings:
AU TGA pregnancy category: C
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were no enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: etidronate
Why do we use etidronate?
etidronate is an Calcium Metabolism Modifiers used to treat Paget Disease and Heterotopic Ossification.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
